| Tbio | Zinc finger protein Aiolos |
Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. Involved in regulating BCL2 expression and controlling apoptosis in T-cells in an IL2-dependent manner.
This gene encodes a member of the Ikaros family of zinc-finger proteins. Three members of this protein family (Ikaros, Aiolos and Helios) are hematopoietic-specific transcription factors involved in the regulation of lymphocyte development. This gene product is a transcription factor that is important in the regulation of B lymphocyte proliferation and differentiation. Both Ikaros and Aiolos can participate in chromatin remodeling. Regulation of gene expression in B lymphocytes by Aiolos is complex as it appears to require the sequential formation of Ikaros homodimers, Ikaros/Aiolos heterodimers, and Aiolos homodimers. Several alternative transcripts encoding different isoforms have been described, as well as some non-protein coding variants. [provided by RefSeq, Apr 2012]
This gene encodes a member of the Ikaros family of zinc-finger proteins. Three members of this protein family (Ikaros, Aiolos and Helios) are hematopoietic-specific transcription factors involved in the regulation of lymphocyte development. This gene product is a transcription factor that is important in the regulation of B lymphocyte proliferation and differentiation. Both Ikaros and Aiolos can participate in chromatin remodeling. Regulation of gene expression in B lymphocytes by Aiolos is complex as it appears to require the sequential formation of Ikaros homodimers, Ikaros/Aiolos heterodimers, and Aiolos homodimers. Several alternative transcripts encoding different isoforms have been described, as well as some non-protein coding variants. [provided by RefSeq, Apr 2012]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Arthritis, Rheumatoid | 174 | 0.0 | 0.0 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 49 | 0.0 | 0.0 |
| Disease | Target Count |
|---|---|
| Precursor Cell Lymphoblastic Leukemia Lymphoma | 43 |
| Rheumatoid arthritis | 1191 |
| Disease | Target Count | P-value |
|---|---|---|
| psoriasis | 6694 | 4.9e-62 |
| lung carcinoma | 2843 | 2.5e-13 |
| osteosarcoma | 7950 | 1.4e-04 |
| lung cancer | 4740 | 1.7e-04 |
| gastric cancer | 459 | 1.2e-03 |
| interstitial cystitis | 2312 | 1.7e-03 |
| primary Sjogren syndrome | 735 | 2.5e-03 |
| ulcerative colitis | 1819 | 2.6e-03 |
| invasive ductal carcinoma | 2951 | 1.9e-02 |
| ductal carcinoma in situ | 1745 | 2.8e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Multiple myeloma | 1332 | 4.46 | 2.2 |
| Disease | Target Count |
|---|---|
| Chronic Lymphocytic Leukemia | 262 |
| acute lymphocytic leukemia | 33 |
| Disease | log2 FC | p |
|---|---|---|
| ductal carcinoma in situ | 1.400 | 2.8e-02 |
| gastric cancer | 1.400 | 1.2e-03 |
| interstitial cystitis | 1.500 | 1.7e-03 |
| invasive ductal carcinoma | 1.100 | 1.9e-02 |
| lung cancer | -1.800 | 1.7e-04 |
| lung carcinoma | -1.400 | 2.5e-13 |
| osteosarcoma | -1.925 | 1.4e-04 |
| primary Sjogren syndrome | 1.300 | 2.5e-03 |
| psoriasis | 1.600 | 4.9e-62 |
| ulcerative colitis | 1.300 | 2.6e-03 |
| Species | Source | Disease |
|---|---|---|
| Inparanoid OMA EggNOG | ||
| OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG |
MEDIQTNAELKSTQEQSVPAESAAVLNDYSLTKSHEMENVDSGEGPANEDEDIGDDSMKVKDEYSERDEN 1 - 70 VLKSEPMGNAEEPEIPYSYSREYNEYENIKLERHVVSFDSSRPTSGKMNCDVCGLSCISFNVLMVHKRSH 71 - 140 TGERPFQCNQCGASFTQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDALTGHLRTHSVEKPYKCEFCGRS 141 - 210 YKQRSSLEEHKERCRTFLQSTDPGDTASAEARHIKAEMGSERALVLDRLASNVAKRKSSMPQKFIGEKRH 211 - 280 CFDVNYNSSYMYEKESELIQTRMMDQAINNAISYLGAEALRPLVQTPPAPTSEMVPVISSMYPIALTRAE 281 - 350 MSNGAPQELEKKSIHLPEKSVPSERGLSPNNSGHDSTDTDSNHEERQNHIYQQNHMVLSRARNGMPLLKE 351 - 420 VPRSYELLKPPPICPRDSVKVINKEGEVMDVYRCDHCRVLFLDYVMFTIHMGCHGFRDPFECNMCGYRSH 421 - 490 DRYEFSSHIARGEHRALLK 491 - 509 //
